{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:26:59Z","timestamp":1790000819082,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Antisense oligonucleotide (ASO) therapeutics present new opportunities for treating challenging-to-treat diseases. Prediction of concentration\u2013time course in systemic circulation and tissues within the context of large molecule physiologically based pharmacokinetic (PBPK) modelling has proven to be useful in animal-to-human extrapolation and first-in-human dose selection. A human PBPK model was developed and verified using bepirovirsen clinical data to predict plasma pharmacokinetics (PK) and tissue concentrations. Liver and kidney partition coefficient ratios from monkey studies, corrected for plasma unbound fraction in monkeys and humans, informed bepirovirsen concentration predictions in the human liver and kidney. Liver and kidney partition coefficients were calculated to be 2147 and 2822, respectively. All predicted PK parameters in healthy volunteers (except t\n                    <jats:sub>max<\/jats:sub>\n                    ) were within two-folds of observed data. Predicted\n                    <jats:italic>vs<\/jats:italic>\n                    . observed clearance (L\/h), AUC\n                    <jats:sub>0-inf<\/jats:sub>\n                    (\u00b5g.h\/mL) and C\n                    <jats:sub>max<\/jats:sub>\n                    (\u00b5g\/mL) for the 300 mg single dose in healthy volunteers were 2.94, 114.43, and 10.56\n                    <jats:italic>vs<\/jats:italic>\n                    . 2.25, 136.6, and 6.5, respectively. The majority of observed plasma concentrations for all doses were within the 5th and 95th percentiles of the predictions. The evaluated model was used to predict the impact of moderate hepatic impairment on bepirovirsen PK in virtual patients. The predicted\n                    <jats:italic>vs<\/jats:italic>\n                    . observed bepirovirsen exposure in moderate hepatic impairment was 0.9 and 0.7-fold lower, respectively, compared with healthy volunteers. The PBPK model predicted the liver and kidney tissue C\n                    <jats:sub>max<\/jats:sub>\n                    values to be 172 and 132 \u00b5g\/mL, respectively. In conclusion, a PBPK modelling approach for bepirovirsen, an ASO, is presented in this article and offers opportunities for future applications to other oligonucleotide therapeutics.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12248-026-01228-9","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:47:30Z","timestamp":1773434850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PBPK Modelling of Antisense Oligonucleotide Therapeutics: Application for Predicting Plasma and Tissue Pharmacokinetics of Bepirovirsen"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1791-9390","authenticated-orcid":false,"given":"Farzaneh","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-6754","authenticated-orcid":false,"given":"Felix","family":"Stader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4413-066X","authenticated-orcid":false,"given":"Amir S.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1841-9646","authenticated-orcid":false,"given":"Abdallah","family":"Derbalah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-8267","authenticated-orcid":false,"given":"Kunal","family":"Taskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"1228_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1228_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","volume":"76","author":"ST Crooke","year":"2013","unstructured":"Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013;76(2):269\u201376.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1228_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1517\/17425255.2013.737320","volume":"9","author":"RZ Yu","year":"2013","unstructured":"Yu RZ, Grundy JS, Geary RS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol. 2013;9(2):169\u201382.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"1228_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1124\/dmd.106.012401","volume":"35","author":"RZ Yu","year":"2007","unstructured":"Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos. 2007;35(3):460\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1228_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14(1):9\u201321.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"1228_CR6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","volume":"17","author":"M Shadid","year":"2021","unstructured":"Shadid M, Badawi M, Abulrob A. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opin Drug Metab Toxicol. 2021;17(11):1281\u201392.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1228_CR7","unstructured":"US Food and Drug Administration. Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics. 2024 [cited 2026 January 20]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-considerations-development-oligonucleotide-therapeutics. Accessed\u00a022 Sept 2025."},{"key":"1228_CR8","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049.","journal-title":"Elife"},{"issue":"10","key":"1228_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2217\/fvl-2020-0158","volume":"15","author":"A Tallan","year":"2020","unstructured":"Tallan A, Feng Z. Virus spread in the liver: mechanisms, commonalities, and unanswered questions. Future Virol. 2020;15(10):707\u201315.","journal-title":"Future Virol"},{"issue":"7","key":"1228_CR10","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s40121-024-00980-9","volume":"13","author":"AS Youssef","year":"2024","unstructured":"Youssef AS, Ismail M, Han K, Magee M, Nader A. Population pharmacokinetics of Bepirovirsen in healthy participants and participants with chronic hepatitis B virus infection: results from phase 1, 2a, and 2b studies. Infect Dis Ther. 2024;13(7):1515\u201330.","journal-title":"Infect Dis Ther"},{"issue":"11","key":"1228_CR11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/13543784.2023.2277389","volume":"32","author":"LY Mak","year":"2023","unstructured":"Mak LY, Hui RW, Fung J, Seto WK, Yuen MF. Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress. Expert Opin Investig Drugs. 2023;32(11):971\u201383.","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"1228_CR12","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1261\/rna.079699.123","volume":"29","author":"B Spencer-Dene","year":"2023","unstructured":"Spencer-Dene B, Mukherjee P, Alex A, Bera K, Tseng WJ, Shi J, et al. Localization of unlabeled bepirovirsen antisense oligonucleotide in murine tissues using in situ hybridization and CARS imaging. RNA. 2023;29(10):1575\u201390.","journal-title":"RNA"},{"issue":"1","key":"1228_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/jps.10473","volume":"93","author":"RZ Yu","year":"2004","unstructured":"Yu RZ, Geary RS, Monteith DK, Matson J, Truong L, Fitchett J, et al. Tissue disposition of 2\u2019-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci. 2004;93(1):48\u201359.","journal-title":"J Pharm Sci"},{"issue":"10","key":"1228_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpdd.1154","volume":"11","author":"K Han","year":"2022","unstructured":"Han K, Theodore D, McMullen G, Swayze E, McCaleb M, Billioud G, et al. Preclinical and phase 1 assessment of antisense oligonucleotide Bepirovirsen in hepatitis B virus-transgenic mice and healthy human volunteers: support for clinical dose selection and evaluation of safety, tolerability, and pharmacokinetics of single and multiple doses. Clin Pharmacol Drug Dev. 2022;11(10):1191\u2013202.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"1228_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10928-007-9065-1","volume":"34","author":"A Garg","year":"2007","unstructured":"Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687\u2013709.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1228_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67\u201386.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"1228_CR17","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s11095-022-03333-8","volume":"39","author":"JY Jeon","year":"2022","unstructured":"Jeon JY, Ayyar VS, Mitra A. Pharmacokinetic and pharmacodynamic modeling of siRNA therapeutics - a minireview. Pharm Res. 2022;39(8):1749\u201359.","journal-title":"Pharm Res"},{"issue":"5","key":"1228_CR18","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/cpt.3160","volume":"115","author":"A Lumen","year":"2024","unstructured":"Lumen A, Zhang X, Dutta S, Upreti VV. Predicting clinical pharmacokinetics\/pharmacodynamics and impact of organ impairment on siRNA-based therapeutics using a mechanistic physiologically-based pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther. 2024;115(5):1054\u201364.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1228_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10928-021-09761-0","volume":"48","author":"M Monine","year":"2021","unstructured":"Monine M, Norris D, Wang Y, Nestorov I. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. J Pharmacokinet Pharmacodyn. 2021;48(5):639\u201354.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1228_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1089\/oli.2009.0211","volume":"20","author":"MR Alam","year":"2010","unstructured":"Alam MR, Ming X, Dixit V, Fisher M, Chen X, Juliano RL. The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides. 2010;20(2):103\u20139.","journal-title":"Oligonucleotides"},{"issue":"10","key":"1228_CR21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/cpdd.1454","volume":"13","author":"N Noormohamed","year":"2024","unstructured":"Noormohamed N, Lukic T, Marbury TC, Lawitz EJ, Prescott H, Magee M, et al. A phase 1, single-dose study to evaluate the pharmacokinetics and safety of Bepirovirsen in adults with hepatic impairment and healthy participants (B-Assured). Clin Pharmacol Drug Dev. 2024;13(10):1088\u201397.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"1228_CR22","first-page":"2065","volume":"14","author":"F Stader","year":"2025","unstructured":"Stader F, Derbalah A, Zyla A, Liu C, Gardner I, Sepp A. Modeling and simulation identifies endocytosis uptake rate and fraction unbound as important predictors of oligonucleotide pharmacokinetics. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(12):2065\u201373.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"1","key":"1228_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1152\/physrev.1994.74.1.163","volume":"74","author":"B Rippe","year":"1994","unstructured":"Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994;74(1):163\u2013219.","journal-title":"Physiol Rev"},{"issue":"1","key":"1228_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/toxsci\/kfi243","volume":"87","author":"JF Dillman","year":"2005","unstructured":"Dillman JF, Phillips CS. Comparison of non-human primate and human whole blood tissue gene expression profiles. Toxicol Sci. 2005;87(1):306\u201314.","journal-title":"Toxicol Sci"},{"issue":"2","key":"1228_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10928-014-9402-0","volume":"42","author":"A Sepp","year":"2015","unstructured":"Sepp A, Berges A, Sanderson A, Meno-Tetang G. Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory. J Pharmacokinet Pharmacodyn. 2015;42(2):97\u2013109.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3-4","key":"1228_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/bdd.2178","volume":"40","author":"Y Kim","year":"2019","unstructured":"Kim Y, Hatley O, Rhee SJ, Yi S, Lee HA, Yoon S, et al. Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation. Biopharm Drug Dispos. 2019;40(3\u20134):135\u201350.","journal-title":"Biopharm Drug Dispos"},{"key":"1228_CR27","doi-asserted-by":"crossref","unstructured":"Basic anatomical and physiological data for use in radiological protection: reference values. a report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. Ann ICRP. 2002;32(3\u20134):5\u2013265.\u00a0ICRP Publication 89.","DOI":"10.1016\/S0146-6453(03)00002-2"},{"key":"1228_CR28","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/646929","volume":"2010","author":"SL Stephen","year":"2010","unstructured":"Stephen SL, Freestone K, Dunn S, Twigg MW, Homer-Vanniasinkam S, Walker JH, et al. Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. Int J Hypertens. 2010;2010:646929.","journal-title":"Int J Hypertens"},{"issue":"10","key":"1228_CR29","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1124\/dmd.119.086967","volume":"47","author":"SC Humphreys","year":"2019","unstructured":"Humphreys SC, Thayer MB, Lade JM, Wu B, Sham K, Basiri B, et al. Plasma and liver protein binding of N-acetylgalactosamine-conjugated small interfering RNA. Drug Metab Dispos. 2019;47(10):1174\u201382.","journal-title":"Drug Metab Dispos"},{"key":"1228_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114468","volume":"189","author":"K Fairman","year":"2021","unstructured":"Fairman K, Li M, Ning B, Lumen A. Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: opportunities and challenges. Biochem Pharmacol. 2021;189:114468.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1228_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jcph.2121","volume":"63","author":"Y Wang","year":"2023","unstructured":"Wang Y, Diep JK, Yu RZ, Hurh E, Karwatowska-Prokopczuk E, Schneider E, et al. Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2\u2019-MOE and Phosphorothioate Modified Antisense Oligonucleotides. J Clin Pharmacol. 2023;63(1):21\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1228_CR32","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/00000658-196210000-00013","volume":"156","author":"AE Dumont","year":"1962","unstructured":"Dumont AE, Mulholland JH. Alterations in thoracic duct lymph flow in hepatic cirrhosis: significance in portal hypertension. Ann Surg. 1962;156(4):668\u201375.","journal-title":"Ann Surg"},{"issue":"12","key":"1228_CR33","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/jhbp.1112","volume":"29","author":"C Hu","year":"2022","unstructured":"Hu C, Jiang N, Zheng J, Li C, Huang H, Li J, et al. Liver volume based prediction model for patients with hepatitis B virus-related acute-on-chronic liver failure. J Hepatobiliary Pancreat Sci. 2022;29(12):1253\u201363.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"42","key":"1228_CR34","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.3748\/wjg.v28.i42.6068","volume":"28","author":"L Wang","year":"2022","unstructured":"Wang L, Zhang Y, Wu YF, Yue ZD, Fan ZH, Zhang CY, et al. Computed tomography perfusion in liver and spleen for hepatitis B virus-related portal hypertension: a correlation study with hepatic venous pressure gradient. World J Gastroenterol. 2022;28(42):6068\u201377.","journal-title":"World J Gastroenterol"},{"issue":"42","key":"1228_CR35","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e264","volume":"33","author":"SE Kim","year":"2018","unstructured":"Kim SE, Jang ES, Ki M, Gwak GY, Kim KA, Kim GA, et al. Chronic hepatitis B infection is significantly associated with chronic kidney disease: a population-based, matched case-control study. J Korean Med Sci. 2018;33(42):e264.","journal-title":"J Korean Med Sci"},{"key":"1228_CR36","doi-asserted-by":"publisher","unstructured":"Tong G, Zhong W, Peng D, Jiang X, Zhou T, Huang F, et al. Association of reduced renal function with different phase of chronic hepatitis B virus infection. Gut Microbiota and Integrative Wellness. 2022;1. https:\/\/doi.org\/10.54844\/gmiw.2022.0181.","DOI":"10.54844\/gmiw.2022.0181"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01228-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01228-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01228-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:35:26Z","timestamp":1774460126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01228-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01228-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.Salem, A.S.Y.,\u00a0S.H.,\u00a0A.N., and K.T. are employed by GSK and\u00a0may hold financial equities in GSK.Simcyp Simulator V24 is a trademark owned by or licensed to Certara Predictive Technologies, Certara UK Ltd, Sheffield, UK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"72"}}